Level 2 of 6Must-remember
Malaria: recognition, severity and parenteral treatment
Assess, manage and stay safe — enough on its own
The card — assess, manage, caution
Assessment— look, ask, measure
- Ask the one question that makes the diagnosis: does the patient live in, has recently left, or has travelled through a malarious area — malaria cannot be diagnosed clinically with accuracy, and the diagnosis rests on a deliberate question about residence and travel followed by a blood film.
- Time the exposure: falciparum malaria typically presents 7–28 days after exposure (usual incubation 10–21 days but may be longer) with greatest risk within two months of return, while *P. vivax* and *P. ovale* form dormant hepatic hypnozoites and may declare themselves many months, and occasionally more than a year, later.
- Treat fever in a traveller as an emergency: the WHO regards fever a week or more after entering a malaria risk area and up to three months after departure as a medical emergency, and chemoprophylaxis taken faithfully never excludes malaria.
- Expect a non-specific illness: malaise, headache, myalgia, anorexia, nausea, vomiting, abdominal pain, cough and mild diarrhoea, with fever the commonest symptom — continuous or erratic, often reaching 40–41°C with rigors and drenching sweats, classically passing through a cold stage, a hot flush phase and a defervescent sweating phase.
- Do not wait for periodicity: the classical tertian and quartan patterns are seldom seen today because patients are treated before the parasite cycle synchronises, and their absence never excludes malaria.
- Two negatives help enormously: the neck stiffness and photophobia of meningitis do not occur in malaria (genuine meningism means another diagnosis until proved otherwise), and rash and lymphadenopathy are not typical of malaria, pointing instead to dengue, rickettsial infection, enteric fever or acute HIV infection.
- Examine for the signs of severity: conscious level and abnormal behaviour, the depth as well as the rate of respiration, crackles of pulmonary oedema, pallor, the colour of the urine, bleeding from gums or venepuncture sites, left upper quadrant pain suggesting splenic rupture, and retinal haemorrhages on fundoscopy.
- Send a thick and a thin film plus a rapid diagnostic test: the thick film detects (sensitivity about 0.001% parasitaemia) and the thin film speciates and quantifies — "malaria parasites seen" without species and percentage is not a usable result.
- A single negative film does not exclude malaria: repeat thick films at 12–24 hours and again on days 1 and 2, and examine at least three films before declaring malaria unlikely; treat on clinical grounds if confirmation will be delayed and the patient is unwell.
- Check a bedside glucose in every case and repeat it: blood glucose below 2.2 mmol/L is a severity criterion, a perfect imitator of cerebral malaria, and recurs after correction.
- Define severe malaria at the bedside, not from the count — any one of: impaired consciousness or coma (any reduction in Glasgow Coma Scale, delirium, obtundation or abnormal behaviour); prostration (unable to sit or stand unaided, or a child unable to feed or drink); two or more generalised seizures in 24 hours; glucose below 2.2 mmol/L; arterial pH below 7.3 with deep sighing respiration and raised lactate.
- The remaining severity criteria: systolic pressure below 80 mmHg in an adult (below 70 mmHg in a young child); acute pulmonary oedema or ARDS; packed cell volume below 15% or haemoglobin below 50 g/L; spontaneous bleeding or DIC; oliguria with creatinine rising above approximately 265 µmol/L or urea rising despite adequate rehydration; black or cola-coloured urine (blackwater fever); and jaundice with bilirubin above approximately 50 µmol/L plus another organ dysfunction.
- Hyperparasitaemia is contested — take the lower threshold when triaging: Davidson's assumes severe malaria in any non-immune patient above 2%, Kumar & Clark above 1%, CMDT defines a high load as more than 5% of erythrocytes infected or more than 200,000 parasites/µL with counts above 10–20% carrying a particularly poor prognosis, and Harrison's records that more than 100,000/µL (about 2%) increases risk but that some patients have severe malaria with lower counts.
- Read the danger signs that are easy to mislabel: deep acidotic breathing mistaken for "chest infection", a temperature below 36°C, cold peripheries with a preserved blood pressure, any convulsion, dark urine, any bleeding, and — in a neonate — any abnormality at all.
- Check the full blood count: mild thrombocytopenia is usual and a normal platelet count should make you question the diagnosis; fewer than 5% of severe cases bleed significantly.
- Consider the mimics and the co-infections: bacterial sepsis and Gram-negative bacteraemia (clinically indistinguishable; about 6% of children with severe malaria are bacteraemic), bacterial meningitis, dengue, enteric fever, leptospirosis, viral hepatitis A or E, acute HIV seroconversion, rickettsial infection and viral haemorrhagic fever — these diagnoses are not mutually exclusive and the sickest patients frequently have both.
Management— do this, in order
- Decide severity first, because the severity decision determines the route of the drug: oral therapy for uncomplicated disease, immediate parenteral therapy for severe disease and for any patient unable to swallow, and if the species is uncertain, treat as falciparum.
- Intravenous artesunate is the treatment of choice for all patients with severe malaria, in all age groups and in every trimester of pregnancy — 2.4 mg/kg IV at 0, 12 and 24 hours, then once daily; children 20 kg and over as adult, children under 20 kg 3 mg/kg per dose on the same schedule.Doctor / Nurse
- Reconstitute artesunate correctly: 60 mg of dried powder with the supplied ampoule of 5% sodium bicarbonate, shaken until completely clear, diluted to approximately 10 mg/mL with 5% dextrose or 0.9% sodium chloride for intravenous use (about 20 mg/mL for intramuscular use), given as a slow bolus over 1–2 minutes — discard any solution that remains cloudy.Doctor / Nurse
- No venous access: artesunate 2.4 mg/kg IM (under 20 kg 3 mg/kg IM) on the same schedule; where only pre-referral treatment is possible give rectal artesunate 10 mg/kg as a single dose (children 10 mg/kg) and transfer for parenteral therapy.Doctor / Nurse
- No artesunate — quinine dihydrochloride IV: loading dose 20 mg/kg of quinine salt (maximum 1.4 g) IV over 4 hours, then 10 mg/kg (maximum 700 mg) over 4 hours 8-hourly for 48 hours, then 12-hourly until oral therapy is possible; children the same mg/kg regimen, paired with clindamycin rather than doxycycline.Doctor / Nurse
- Omit the quinine loading dose and give 10 mg/kg instead if the patient has received quinine, quinidine or mefloquine within the previous 24 hours; monitor the ECG continuously and reduce the infusion rate if the corrected QT prolongs by more than 25% of baseline; measure glucose every 4–6 hours and co-administer 5–10% dextrose.Doctor / Nurse
- Artemether IM is an inferior alternative: 3.2 mg/kg IM immediately, then 1.6 mg/kg IM daily, same mg/kg regimen in children.Doctor / Nurse
- Continue parenteral treatment for at least 24 hours regardless of how much the patient improves, then, once swallowing is safe, complete a full three-day course of an artemisinin-based combination therapy — or oral artesunate 2 mg/kg once daily to a total cumulative dose of 17–18 mg/kg. Parenteral artesunate alone does not cure malaria.Doctor / Nurse
- Correct hypoglycaemia and recheck: adult 50 mL of 50% glucose intravenously, or 100–200 mL of 10% glucose, then a 10% infusion (glucagon may be ineffective); child 2 mL/kg of 10% glucose intravenously or intraosseously (neonate 2.5 mL/kg), then a 10% infusion — 25% or 50% glucose must not be given peripherally in a child.Doctor / Nurse
- Coma: maintain the airway, nurse on the side (aspiration pneumonia is a recognised and lethal complication), exclude hypoglycaemia and bacterial meningitis, and intubate if the airway cannot be protected.Doctor / NurseNot available at your setup — Endotracheal intubation kit.
- Convulsions: treat promptly with intravenous or rectal diazepam, or paraldehyde where diazepam is unavailable.Doctor / Nurse
- Fluids are a drug with a dose and a toxicity: give balanced crystalloid in small aliquots — 250–500 mL over 15 minutes in a hypotensive adult, 10 mL/kg over 10–20 minutes in a child — reassessing pulse, blood pressure, capillary refill, lung bases and mental state after each.Doctor / Nurse
- Severe anaemia: transfuse fresh whole blood or packed cells (10 mL/kg in children); a packed cell volume below 15% is the widely used threshold where blood is short.Doctor / NurseNot available at your setup — Blood & blood products.
- Pulmonary oedema: nurse at 45 degrees, give oxygen, stop intravenous fluids and give a diuretic; add CPAP or intubation with PEEP for life-threatening hypoxaemia — venesection of 250 mL appears in WHO guidance as an immediate measure but must never be used in a patient who is anaemic or shocked.Doctor / Nurse
- Hyperpyrexia: tepid sponging, fanning and paracetamol.
- Give empirical antibacterial therapy alongside the antimalarial in every child with severe malaria in an endemic area (with activity against non-typhoidal *Salmonella* from the outset), in every adult with a parasitaemia above 20%, in every patient with shock, and in any severely ill patient who fails to respond or deteriorates unexpectedly — ideally take blood cultures in all severe malaria.Doctor / NurseNot available at your setup — Blood culture.
- Uncomplicated falciparum malaria — oral ACT: artemether–lumefantrine (20/120 mg) 4 tablets orally twice daily for 3 days, or the 6-dose schedule of 4 tablets at 0, 8, 24, 36, 48 and 60 hours, each dose with milk, yoghurt or a fatty meal because lumefantrine bioavailability is considerably increased by fat; observe for vomiting for one hour and repeat any dose vomited within that hour.
- Non-falciparum malaria: chloroquine approximately 25 mg base/kg over three days — 600 mg base orally, then 300 mg at 6, 24 and 48 hours (CMDT expresses this as chloroquine phosphate 1 g then 500 mg at 6, 24 and 48 hours); children 10 mg base/kg immediately then 5 mg base/kg at 6, 24 and 48 hours — then radical cure with primaquine 0.25–0.5 mg/kg per day orally for 14 days (commonly 30 mg base daily) once G6PD status is known.
Caution— what harms
- Never use an artemisinin derivative as monotherapy — it selects resistance and fails to cure.
- The commonest dosing error is giving a child under 20 kg the adult 2.4 mg/kg dose instead of 3 mg/kg — check the weight before drawing up.Doctor / Nurse
- Never stop after the parenteral drug: parenteral artesunate alone does not cure malaria, and a patient who stops after three days of vivax treatment without radical cure will relapse.
- Never use mefloquine as follow-on treatment because of the increased risk of the post-malaria neurological syndrome.
- Never give the four harmful ancillary treatments: glucocorticoids, prophylactic phenobarbitone, heparin and adrenaline.Doctor / Nurse
- Never give 25% or 50% glucose peripherally in a child, and never treat the coma without first excluding hypoglycaemia below 2.2 mmol/L.Doctor / Nurse
- Restrict fluid the moment urea or age- and weight-adjusted creatinine rises despite adequate rehydration — a randomised trial of fluid boluses in African children with severe febrile illness, much of it malaria, found *increased* mortality, and non-cardiogenic pulmonary oedema is readily precipitated by injudicious fluids.Not available at your setup — Renal function (creatinine/urea).
- Do not let a normal or falling parasite count reassure you: sequestration means the peripheral count seriously underestimates the true burden, organ dysfunction occurs at apparently modest counts, and the count never overrules the clinical picture in either direction.
- Do not trust one negative test: repeat thick films at 12–24 hours and on days 1 and 2 (at least three films), and remember HRP2 rapid tests are falsely negative with dual *pfhrp2/pfhrp3* gene deletions or occasionally at very high parasitaemia, and falsely positive for weeks after a treated infection so they cannot judge response or diagnose a second episode.
- Do not use serology, and do not rely on PCR for primary diagnosis — serology is of no diagnostic value in acute malaria, and in endemic populations PCR sensitivity is a liability because untreated subclinical infection is common.
- Do not treat falciparum malaria with chloroquine or sulfadoxine–pyrimethamine — *P. falciparum* is resistant to both in most areas.
- Do not stop quinine for cinchonism — tinnitus, high-tone hearing loss, nausea, vomiting, dysphoria and postural hypotension are expected and are not a reason to stop treating severe malaria; do not reduce the dose for acute malarial renal insufficiency in the first 48 hours; but do watch for quinine-induced hyperinsulinaemic hypoglycaemia, a genuine cause of death, especially in pregnancy.Doctor / Nurse
- Do not give primaquine in pregnancy — pregnant women with vivax or ovale malaria receive suppressive chloroquine 5 mg base/kg weekly until one month after delivery, after which radical treatment may be given.
- Do not re-treat for persisting gametocytes: falciparum gametocytes are unaffected by most antimalarials and their persistence after a full course implies neither resistance nor a need to re-treat.
Refer / escalate
Any patient meeting a single WHO severe-malaria criterion, any non-immune patient with a parasitaemia above 1–2%, any patient unable to swallow, any pregnant woman, any child under five with prostration or convulsion, and any neonate with any abnormality needs immediate parenteral artesunate and urgent referral — give the first artesunate dose (or rectal artesunate 10 mg/kg if nothing else is available) before transfer, never after.
Read the full lesson free
Create a free account to unlock every page, the level exams, and progress tracking.
Sign up freeLog in